Silence Therapeutics announces that the entire shareholding held by Introgen has been placed with existing and new shareholder
21-Jan-2008
The shares were purchased at the prevailing market price of 56.75p per share and as necessary further regulatory announcements concerning this transaction will follow in due course.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.